Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANAS HADEH

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1437360187
CMS profile
774363
Location
WESTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$174,193.35

164 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANAS HADEH

NPI 1437360187 · CMS profile ID 774363

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

WESTON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437360187?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANAS HADEH, NPI 1437360187, CMS profile ID 774363. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437360187?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANAS HADEH, NPI 1437360187, CMS profile ID 774363. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437360187?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANAS HADEH, NPI 1437360187, CMS profile ID 774363, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–164 of 164 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1437360187?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

164 matching records · $174,193.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 164 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–164 of 164.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $2,150.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105366501 CMS
Grifols USA, LLC $5,637.5001/30/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124721011 CMS
Grifols USA, LLC $169.8101/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124721021 CMS
GENZYME CORPORATION $2,936.0001/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139960649 CMS
GENZYME CORPORATION $128.8201/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139960651 CMS
Grifols USA, LLC $529.4201/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124721013 CMS
Grifols USA, LLC $473.3801/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124721017 CMS
Grifols USA, LLC $50.1901/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124721015 CMS
AstraZeneca Pharmaceuticals LP $32.2801/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105294384 CMS
AstraZeneca Pharmaceuticals LP $124.9901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104511890 CMS
AstraZeneca Pharmaceuticals LP $28.1401/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104596404 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.7901/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118008947 CMS
Actelion Pharmaceuticals US, Inc. $26.8601/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078881167 CMS
Grifols USA, LLC $204.3301/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124721019 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,321.81 90
PY2020 $25,247.95 46
PY2021 $53,157.17 89
PY2022 $92,152.11 116
PY2023 $142,448.67 151
PY2024 $174,193.35 164
PY2025 $270,563.55 256

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $24,192.09 17
PY2024 Principal investigator $4,432.66 4
PY2020 Principal investigator $10,100.00 4
PY2019 Principal investigator $4,916.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737574
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737576
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737578
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 12/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737580
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 11/19/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737582
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737584
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 11/19/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737586
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 11/19/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737588
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 11/19/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737590
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 11/19/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737592
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737562
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737564
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737566
Principal investigator 1 Boehringer Ingelheim International GmbH $15.39 11/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737568
Principal investigator 1 Boehringer Ingelheim International GmbH $434.52 11/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737570
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/01/2025 Non-covered Recipient Entity
Cleveland Clinic Florida Weston Hospital-Primary Care Practice
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220737572
Principal investigator 1 Mannkind Corporation $22,500.00 05/16/2025 Non-covered Recipient Entity
CLEVELAND CLINIC
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250898496